Free Trial
NASDAQ:AARD

Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Aardvark Therapeutics logo
$10.50 +0.49 (+4.90%)
As of 04:00 PM Eastern

About Aardvark Therapeutics Stock (NASDAQ:AARD)

Key Stats

Today's Range
$9.67
$10.81
50-Day Range
$7.00
$12.86
52-Week Range
$4.88
$19.58
Volume
22,053 shs
Average Volume
112,131 shs
Market Capitalization
$227.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.25
Consensus Rating
Buy

Company Overview

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Receive AARD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AARD Stock News Headlines

Cantor Fitzgerald Analysts Raise Earnings Estimates for AARD
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. Now… as new tariffs take effect, gold is breaking records again. You've hopefully already seen this in action… but gold is surpassing $3,000 per ounce for the first time EVER.
See More Headlines

AARD Stock Analysis - Frequently Asked Questions

Aardvark Therapeutics' stock was trading at $13.30 on January 1st, 2025. Since then, AARD shares have decreased by 21.1% and is now trading at $10.50.
View the best growth stocks for 2025 here
.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01.

Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO.

Aardvark Therapeutics' quiet period expired on Tuesday, March 25th. Aardvark Therapeutics had issued 5,888,000 shares in its public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Aardvark Therapeutics' top institutional investors include Decheng Capital LLC (18.06%), Cormorant Asset Management LP (3.69%), Braidwell LP (2.30%) and Adage Capital Partners GP L.L.C. (1.15%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends
.

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
5/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AARD
Previous Symbol
NASDAQ:AARD
Web
N/A
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.25
High Stock Price Target
$50.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+190.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$233.23 million
Optionable
N/A
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:AARD) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners